Research programme: P2Y receptor agonists - Bar-Ilan University/Innodia

Drug Profile

Research programme: P2Y receptor agonists - Bar-Ilan University/Innodia

Alternative Names: ID-1738

Latest Information Update: 10 Mar 2009

Price : $50

At a glance

  • Originator Bar-Ilan University
  • Class Small molecules
  • Mechanism of Action Purinoceptor P2U agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 17 Jul 2008 Innodia has been acquired by BELLUS Health
  • 30 Mar 2007 Preclinical development is ongoing for ID 1738 in Type-2 diabetes mellitus
  • 25 Nov 2003 Preclinical trials in Type-2 diabetes mellitus in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top